Selected article for: "international license and old age"
Author: Penghui Yang; Yibo Ding; Zhe Xu; Rui Pu; Ping Li; Jin Yan; Jiluo Liu; Fanping Meng; Lei Huang; Lei Shi; Tianjun Jiang; Enqiang Qin; Min Zhao; Dawei Zhang; Peng Zhao; Lingxiang Yu; Zhaohai Wang; Zhixian Hong; Zhaohui Xiao; Qing Xi; Dexi Zhao; Peng Yu; Caizhong Zhu; Zhu Chen; Shaogeng Zhang; Junsheng Ji; Guangwen Cao; Fusheng Wang
Title: Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China
  • Document date: 2020_3_3
    • ID: 2vdvswda_41
    Snippet: Third, half patients are still hospitalized. The disease course of severe patients might be prolonged by therapeutic regimens including corticosteroids. 28 Finally, we characterized the epidemiological features including the incubation period, time to RT-PCR conversion of SARS-CoV-2, COVID-19 course, and the transmissibility SARS-CoV-2 in asymptomatic carriers. Old age, hypertension, interleukin-6, and CD8 + T cell exhaustion were significantly a.....
    Document: Third, half patients are still hospitalized. The disease course of severe patients might be prolonged by therapeutic regimens including corticosteroids. 28 Finally, we characterized the epidemiological features including the incubation period, time to RT-PCR conversion of SARS-CoV-2, COVID-19 course, and the transmissibility SARS-CoV-2 in asymptomatic carriers. Old age, hypertension, interleukin-6, and CD8 + T cell exhaustion were significantly associated with the development of pneumonia. Circulating interleukin-6 and lactate independently predicted COVID-19 progression. CD8 + T cell exhaustion might be important in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • asymptomatic carrier and incubation period: 1, 2, 3, 4, 5, 6, 7
    • asymptomatic carrier and International license: 1
    • asymptomatic carrier and old age: 1
    • cc NC ND International license and disease course: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cc NC ND International license and incubation period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and old age: 1, 2, 3, 4
    • cc NC ND International license and pneumonia development: 1, 2
    • cell exhaustion and disease course: 1, 2, 3, 4, 5
    • cell exhaustion and old age: 1, 2, 3
    • disease course and half patient: 1
    • disease course and incubation period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease course and independently predict: 1
    • disease course and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • disease course and old age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease course and pneumonia development: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • epidemiological feature and incubation period: 1
    • incubation period and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • incubation period and old age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20